BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 38543737)

  • 1. Effects of HCV Clearance with Direct-Acting Antivirals (DAAs) on Liver Stiffness, Liver Fibrosis Stage and Metabolic/Cellular Parameters.
    Ferreira J; Bicho M; Serejo F
    Viruses; 2024 Feb; 16(3):. PubMed ID: 38543737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Inflammatory/Immune Response and Cytokine Polymorphisms in the Severity of Chronic Hepatitis C (CHC) before and after Direct Acting Antiviral (DAAs) Treatment.
    Ferreira J; Oliveira M; Bicho M; Serejo F
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic fibrosis changes in patients with chronic hepatitis C infection who respond to direct-acting antivirals.
    Alswat K; Al-Sohaibani F; Khathlan A; Bashmail A; Alanazi M; Kurdi A; Almakadma AH; Al-Hamoudi W
    Ann Saudi Med; 2022; 42(2):89-95. PubMed ID: 35380056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients.
    Adinolfi LE; Nevola R; Guerrera B; D'Alterio G; Marrone A; Giordano M; Rinaldi L
    J Gastroenterol Hepatol; 2018 Jul; 33(7):1379-1382. PubMed ID: 29228501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND SYSTEMIC ARTERIAL HYPERTENSION ARE ASSOCIATED WITH HEPATIC NECROINFLAMMATORY ACTIVITY IN PATIENTS WITH CHRONIC HEPATITIS C.
    Souza GHPE; Silva LD; Vieira DA; Rocha GA; Lima AS; Vidigal PVT
    Arq Gastroenterol; 2023; 60(3):287-299. PubMed ID: 37792757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study.
    Lee H; Chien RN; Pao LH; Kuo CJ; Huang PH; Chang ML
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Direct-Acting Antiviral Therapy on Liver Fibrosis Regression among People with Chronic HCV Infection: Results from a Real-Life Cohort in Patients Who Achieved Sustained Virological Response.
    García-Ros A; Morán S; Núñez V; García-Ros G; Ruiz G; García-Solano J
    Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109770
    [No Abstract]   [Full Text] [Related]  

  • 8. Virus Elimination by Direct-Acting Antiviral Agents Impacts Glucose Homeostasis in Chronic Hepatitis C Patients.
    Cheng CH; Chu CY; Chen HL; Lin IT; Wu CH; Lee YK; Bair MJ
    Front Endocrinol (Lausanne); 2021; 12():799382. PubMed ID: 35095765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs.
    El Sagheer G; Soliman E; Ahmad A; Hamdy L
    Libyan J Med; 2018 Dec; 13(1):1435124. PubMed ID: 29451090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Serum Lipids with Hepatic Steatosis, Stage of Liver Fibrosis and Viral Load in Chronic Hepatitis C.
    Valkov I; Ivanova R; Alexiev A; Antonov K; Mateva L
    J Clin Diagn Res; 2017 Aug; 11(8):OC15-OC20. PubMed ID: 28969178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement in Liver Stiffness in Pediatric Patients with Hepatitis C Virus after Treatment with Direct Acting Antivirals.
    Mogahed EA; El-Karaksy H; Abdullatif H; Yasin NA; Nagy A; Alem SA; Eldeen HG; El-Raziky MS
    J Pediatr; 2021 Jun; 233():126-131. PubMed ID: 33577805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors for Fibrosis Regression in Chronic HCV Patients after the Treatment with DAAS: Results of a Real-world Cohort Study.
    Soliman H; Ziada D; Salama M; Hamisa M; Badawi R; Hawash N; Selim A; Abd-Elsalam S
    Endocr Metab Immune Disord Drug Targets; 2020; 20(1):104-111. PubMed ID: 31448717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triglyceride-rich lipoproteins and insulin resistance in patients with chronic hepatitis C receiving direct-acting antivirals.
    Casas-Deza D; Espina S; Martínez-Sapiña A; Del Moral-Bergos R; Garcia-Sobreviela MP; Lopez-Yus M; Calmarza P; Bernal-Monterde V; Arbones-Mainar JM
    Atherosclerosis; 2023 Jun; 375():59-66. PubMed ID: 37245427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of liver stiffness measurement, acoustic radiation force impulse measurements, and noninvasive fibrosis markers after direct-acting antivirals for hepatitis C virus G4 recurrence post living donor liver transplantation: Egyptian cohort.
    Alem SA; Said M; Anwar I; Abdellatif Z; Elbaz T; Eletreby R; AbouElKhair M; El-Serafy M; Mogawer S; El-Amir M; El-Shazly M; Hosny A; Yosry A
    J Med Virol; 2018 Sep; 90(9):1508-1515. PubMed ID: 29718546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication.
    Kang Q; Xu J; Luo H; Tan N; Chen H; Cheng R; Pan J; Han Y; Yang Y; Liu D; Xi H; Yu M; Xu X
    J Viral Hepat; 2021 Sep; 28(9):1284-1292. PubMed ID: 34105867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct acting antivirals are associated with more liver stiffness regression than pegylated interferon therapy in chronic hepatitis C patients.
    Abdelsameea E; Alsebaey A; Abdel-Samiee M; Abdel-Razek W; Salama M; Waked I
    Expert Rev Anti Infect Ther; 2021 Aug; 19(8):1053-1059. PubMed ID: 33307880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy with Oral Directly Acting Agents in Hepatitis C Infection Is Associated with Reduction in Fibrosis and Increase in Hepatic Steatosis on Transient Elastography.
    Rout G; Nayak B; Patel AH; Gunjan D; Singh V; Kedia S; Shalimar
    J Clin Exp Hepatol; 2019; 9(2):207-214. PubMed ID: 31024203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin resistance is a major determinant of liver stiffness in nondiabetic patients with HCV genotype 1 chronic hepatitis.
    Petta S; Cammà C; DI Marco V; Calvaruso V; Enea M; Bronte F; Butera G; Cabibi D; Craxì A
    Aliment Pharmacol Ther; 2009 Sep; 30(6):603-13. PubMed ID: 19563503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term effects of direct-acting antiviral agents on inflammation and gut microbiota in hepatitis C-infected patients.
    Pérez-Matute P; Íñiguez M; Villanueva-Millán MJ; Recio-Fernández E; Vázquez AM; Sánchez SC; Morano LE; Oteo JA
    Eur J Intern Med; 2019 Sep; 67():47-58. PubMed ID: 31221551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies.
    Origa R; Ponti ML; Filosa A; Galeota Lanza A; Piga A; Saracco GM; Pinto V; Picciotto A; Rigano P; Madonia S; Rosso R; D'Ascola D; Cappellini MD; D'Ambrosio R; Tartaglione I; De Franceschi L; Gianesin B; Di Marco V; Forni GL;
    Am J Hematol; 2017 Dec; 92(12):1349-1355. PubMed ID: 28929515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.